Tarveda to Present Updates on the Development of Its Miniaturized
Drug Conjugates at Upcoming Scientific and Medical Meetings

July 17, 2017 10:00 AM Eastern Daylight Time

WATERTOWN, Mass.--(EON: Enhanced Online News)--Tarveda
Therapeutics, Inc., a clinical stage biopharmaceutical company
discovering and developing Pentarins™ as a new class of potent and
selective cancer medicines, today announced that the company will
present preclinical data related to its lead candidate, PEN-221, and
provide an update on the Company’s novel Pentarin platform at upcoming
scientific and medical meetings.

Gitanjali Sharma, Ph.D., will discuss the optimization of the
formulation of PEN-221 leading to complete tumor regression in
SSTR2-expressing cancer models, during a poster presentation at the 2017
Controlled Release Society Annual Meeting & Exposition in Boston.

Presentation Title: Developing Potent and
Selective Miniaturized Conjugates for the Treatment of Patients With
Solid TumorsDate and Time: 11:30am to
12:00pm ET on Tuesday, July 25, 2017

About Pentarins™

Tarveda is developing Pentarins, potent and selective miniaturized drug
conjugates with high affinity for specific cell surface and
intracellular targets. Pentarins are engineered to bind to their tumor
cell targets and provide sustained release of their potent therapeutic
payloads deep into solid tumor tissue. Comprised of a targeting ligand
conjugated to a potent cancer cell-killing agent through an optimized
chemical linker, Pentarins are designed to overcome the deficits of both
larger antibody drug conjugates and small molecules that limit their
therapeutic effectiveness against solid tumors. Together, the components
of Tarveda’s Pentarins have distinct, yet synergistic, anticancer
attributes: the small size of Pentarins allows for effective penetration
and distribution into the tumor tissue, the ligand’s targeting ability
allows for specific binding and retention in tumor cells, and the
chemical linker is tuned to optimize the release of the potent,
cell-killing payload inside the cancer cells for efficacy.

About Tarveda Therapeutics, Inc.

Tarveda Therapeutics, Inc. discovers and develops Pentarins™, a new
class of potent and selective miniaturized drug conjugates with enhanced
targeting capabilities for the treatment of solid cancer tumors.
Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized drug
conjugate that targets the somatostatin receptor 2 (SSTR2) for treatment
of patients with neuroendocrine and small cell lung cancers. PEN-221
comprises a highly selective peptide that targets SSTR2 linked to the
potent cytotoxic DM1 through a cleavable linker. Tarveda is also
advancing its HSP90 drug conjugate platform with lead drug candidate
PEN-866, which is a miniaturized HSP90 targeting drug conjugate that
comprises a small molecule HSP90 targeting ligand conjugated to SN-38,
the highly potent, active metabolite of irinotecan. Tarveda’s strategy
includes developing its own proprietary Pentarins as well as applying
the Pentarin platform to enhance the effectiveness of the targeting
moieties and novel payloads of its pharmaceutical collaborators. www.tarveda.com

WATERTOWN, Mass.--(EON: Enhanced Online News)--Tarveda Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective ca... more »

WATERTOWN, Mass.--(EON: Enhanced Online News)--Tarveda to Present on Lead Intracellular Targeting Pentarin PEN-866 at 2017 American Association of Pharmaceutical Scientists National Biotechnology C... more »